0
Pulmonary Procedures |

Efficacy of Bronchoscopic Closure of Bronchopleural Fistula With Amplatzer Devices: Long Term Follow-up

Oren Fruchter, MD; Bayya Abed El Raouf, MD; Milton Saute, MD; Elchanan Bruckheimer, MBBS; Nader Abdel Rachman, MD; Leonardo Fuks, MD; Mordechai Kramer, MD
Author and Funding Information

Rabin Medical Center, Jerusalem, Israel


Chest. 2014;145(3_MeetingAbstracts):497A. doi:10.1378/chest.1835656
Text Size: A A A
Published online

Abstract

SESSION TITLE: Bronchoscopy & Interventional Procedures

SESSION TYPE: Slide Presentations

PRESENTED ON: Monday, March 24, 2014 at 09:00 AM - 10:30 AM

PURPOSE: The development of Broncho-pleural fistula (BPF) is associated with high rate of morbidity and mortality. We have developed a minimally invasive method of bronchoscopic closure of BPF using Amplazer devices (AD) and Amplazer vascular plugs (AVP), with excellent short-term results. The aim of the present report was to explore the long term outcome of patients and the durability of this novel modality of BPF treatment.

METHODS: A total of 31 central BPF in 31 patients (mean age 66.8 years, range 19-91) were sealed under moderate sedation bronchoscopically by either AD (N = 19) or AVP (N = 12). The average follow-up period was 17.6 months (range 1-68 months)

RESULTS: The main etiology for BPF was surgery (N = 24), pneumonectomy (N =14) or lobectomy/segmentectomy (N = 10). The underlying disease was lung cancer either primary (N = 20) or metastatic (n = 2). The immediate success rate was 96% as symptoms related to BPF disappeared in 30/31 of the patients. Short-term (less than 30 days) mortality was 4/31 (13%). At follow-up, 14 patients (45%) are still alive. Out of 12 patients with late mortality, in 5 patients (41 %) the death was directly related to cancer relapse, and no patient died due to BPF recurrence.

CONCLUSIONS: Conclusion: Endobronchial closure of BPF using both types of Amplatzer occluders (AD, AVP) is a minimally invasive effective modality of treatment with high safety profile and satisfactory long term outcome considering the poor prognosis in this particular group of patients

CLINICAL IMPLICATIONS: Our work can help other physicians to consider Amplatzer occluders as a safe and effective modality of treatment in a poor prognosis group of patients and bring to crucial therapeutic decisions.

DISCLOSURE: The following authors have nothing to disclose: Oren Fruchter, Bayya Abed El Raouf, Milton Saute, Elchanan Bruckheimer, Nader Abdel Rachman, Leonardo Fuks, Mordechai Kramer

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543